PML
MCID: PRG009
MIFTS: 52

Progressive Multifocal Leukoencephalopathy (PML) malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Progressive Multifocal Leukoencephalopathy

Aliases & Descriptions for Progressive Multifocal Leukoencephalopathy:

Name: Progressive Multifocal Leukoencephalopathy 12 50 51 56 14
Leukoencephalopathy, Progressive Multifocal 50 42 69
Pml 12 50 56
Leukoencephalopathy Progressive Multifocal 52
Progressive Multifocal Leukoencephalitis 56

Characteristics:

Orphanet epidemiological data:

56
progressive multifocal leukoencephalopathy
Inheritance: Not applicable; Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:643
ICD10 33 A81.2
ICD9CM 35 046.3
MeSH 42 D007968
NCIt 47 C26815
SNOMED-CT 64 22255007
Orphanet 56 ORPHA217260
ICD10 via Orphanet 34 A81.2
MESH via Orphanet 43 D007968
UMLS via Orphanet 70 C0023524
UMLS 69 C0023524

Summaries for Progressive Multifocal Leukoencephalopathy

NINDS : 51 Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons).  Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses.  The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma).  Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosis -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well.  PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS).  Studies estimate that prior to effective antiretroviral therapy, as many as 5 percent of persons infected with HIV-1 eventually develop PML that is an AIDS-defining illness.  However, current HIV therapy using antiretroviral drugs (ART), which effectively restores immune system function, allows as many as half of all HIV-PML patients to survive, although they may sometimes have an inflammatory reaction in the regions of the brain affected by PML.  The symptoms of PML are diverse, since they are related to the location and amount of damage in the brain, and may evolve over the course of several weeks to months  The most prominent symptoms are clumsiness; progressive weakness; and visual, speech, and sometimes personality changes.  The progression of deficits leads to life-threatening disability and (frequently) death.  A diagnosis of PML can be made following brain biopsy or by combining observations of a progressive course of the disease, consistent white matter lesions visible on a magnetic resonance imaging (MRI) scan, and the detection of the JC virus in spinal fluid.

MalaCards based summary : Progressive Multifocal Leukoencephalopathy, also known as leukoencephalopathy, progressive multifocal, is related to leukemia, acute promyelocytic, somatic and acute promyelocytic leukemia pml/rara type. An important gene associated with Progressive Multifocal Leukoencephalopathy is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Natalizumab and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Disease Ontology : 12 A viral infectious disease that involves reactivation of JC polyomavirus in immune-compromised individuals which causes the loss of white matter (which is made up of myelin, a substance the surrounds and protects nerve fibers) in multiple areas of the brain. The symptoms include hemiparesis, aphasia, dysarthria, hemianopia, cognitive impairment and coma.

NIH Rare Diseases : 50 progressive multifocal leukoencephalopathy (pml) is a neurological disorder that damages the myelin that covers and protects nerves in the white matter of the brain. it is caused by the jc virus (jcv). by age 10, most people have been infected with this virus, but it rarely causes symptoms unless the immune system becomes severely weakened. the disease occurs, rarely, in organ transplant patients; people undergoing chronic corticosteroid or immunosuppressive therapy; and individuals with cancer, such as hodgkin’s disease, lymphoma, and sarcoidosis.  pml is most common among individuals with acquired immune deficiency syndrome (aids). last updated: 4/1/2011

Wikipedia : 71 Progressive multifocal leukoencephalopathy (PML) is a rare and usually fatal viral disease characterized... more...

Related Diseases for Progressive Multifocal Leukoencephalopathy

Diseases related to Progressive Multifocal Leukoencephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
id Related Disease Score Top Affiliating Genes
1 leukemia, acute promyelocytic, somatic 12.3
2 acute promyelocytic leukemia pml/rara type 12.1
3 lymphoma 10.4
4 leukemia 10.3
5 steatitis 10.3 IL2 TNF
6 systemic lupus erythematosus 10.2
7 lupus erythematosus 10.2
8 autosomal dominant deafness-onychodystrophy syndrome 10.2 IL2 TNF
9 thymic neuroendocrine carcinoma 10.2 IL2 TNF
10 submandibular gland disease 10.2 CD40LG TNF
11 hodgkin lymphoma 10.2
12 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IL2 TNF
13 chronic lymphocytic leukemia 10.1
14 dermatitis herpetiformis 10.1 CD40LG TNF
15 lichen disease 10.1 HTR2A IL2 TNF
16 hemangioma of orbit 10.1 CD40LG IL2 TNF
17 twin-to-twin transfusion syndrome 10.1 BCL2 TNF
18 tularemia 10.1 CD40LG IL2 TNF
19 endogenous depression 10.1 CD40LG IL2 TNF
20 tuberculosis 10.1 CD40LG IL2 TNF
21 newcastle disease 10.1 CD40LG IL2 TNF
22 myiasis 10.1 CD40LG IL2 TNF
23 spotted fever 10.1 CD40LG TNF
24 anterior foramen magnum meningioma 10.1 CD40LG IL2 TNF
25 acute dacryoadenitis 10.1 CD40LG IL2 TNF
26 pemphigus vulgaris, familial 10.1 CD40LG IL2 TNF
27 nonspecific interstitial pneumonia 10.1 CD40LG IL2 TNF
28 uterus interstitial leiomyoma 10.1 CD40LG IL2 TNF
29 foodborne botulism 10.1 CD40LG IL2 TNF
30 motor peripheral neuropathy 10.1 CD40LG STAT1 TNF
31 anus leiomyosarcoma 10.1 CD40LG IL2 TNF
32 hyperimmunoglobulin syndrome 10.1 CD40LG STAT1 TNF
33 depressed scar 10.1 CD40LG STAT1 TNF
34 acute allergic sanguinous otitis media 10.1 BCL2 IL2
35 bone angioendothelial sarcoma 10.1 CD40LG IL2 TNF
36 rheumatic disease 10.1
37 acquired immunodeficiency syndrome 10.1
38 atrial septal defect 6 10.1 CD40LG IL2 TNF
39 membranoproliferative glomerulonephritis 10.1 CD40LG IL2 TNF
40 rheumatoid arthritis 10.0
41 arthritis 10.0
42 follicular lymphoma 10.0
43 spinal polio 10.0 CD40LG MBP
44 gastroduodenitis 10.0 CD40LG IL2 STAT1
45 primary tubular proximal acidosis 10.0 BCL2 IL2
46 chronic duodenal ileus 10.0 CD40LG MBP
47 gonococcal synovitis 10.0 CD40LG STAT1
48 hiv-1 10.0
49 tremor 10.0
50 heart conduction disease 10.0 CD40LG IL2 STAT1 TNF

Graphical network of the top 20 diseases related to Progressive Multifocal Leukoencephalopathy:



Diseases related to Progressive Multifocal Leukoencephalopathy

Symptoms & Phenotypes for Progressive Multifocal Leukoencephalopathy

GenomeRNAi Phenotypes related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 IL2 PDCD1 STAT1 TNF BCL2 CD40LG
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 PDCD1 STAT1 TNF BCL2 CD40LG IL2

MGI Mouse Phenotypes related to Progressive Multifocal Leukoencephalopathy:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 MBP MECP2 PDCD1 STAT1 TNF BCL2
2 cardiovascular system MP:0005385 10.18 BCL2 CD40LG IGHMBP2 IL2 ITGA4 MECP2
3 behavior/neurological MP:0005386 10.14 IGHMBP2 IL2 MBP MECP2 STAT1 TNF
4 homeostasis/metabolism MP:0005376 10.09 BCL2 CD40LG IGHMBP2 IL2 MBP MECP2
5 endocrine/exocrine gland MP:0005379 10.08 BCL2 CD40LG HTR2A IL2 MECP2 PDCD1
6 mortality/aging MP:0010768 10.07 BCL2 CD40LG IGHMBP2 IL2 ITGA4 MBP
7 hematopoietic system MP:0005397 10.06 BCL2 CD40LG IL2 ITGA4 MBP PDCD1
8 immune system MP:0005387 10.06 STAT1 TNF BCL2 CD40LG IL2 ITGA4
9 digestive/alimentary MP:0005381 9.97 IL2 STAT1 TNF BCL2 HTR2A IGHMBP2
10 muscle MP:0005369 9.8 BCL2 HTR2A IGHMBP2 PDCD1 STAT1 TNF
11 nervous system MP:0003631 9.76 BCL2 CD40LG IGHMBP2 MBP MECP2 PDCD1
12 neoplasm MP:0002006 9.65 BCL2 IL2 PDCD1 STAT1 TNF
13 respiratory system MP:0005388 9.43 BCL2 IGHMBP2 IL2 MECP2 PDCD1 TNF
14 vision/eye MP:0005391 9.17 BCL2 IL2 MBP MECP2 PDCD1 STAT1

Drugs & Therapeutics for Progressive Multifocal Leukoencephalopathy

Drugs for Progressive Multifocal Leukoencephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4 189261-10-7
2
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Interferon beta-1b Approved Phase 4 145155-23-3
5 interferons Phase 4
6 Adjuvants, Immunologic Phase 4
7 Gastrointestinal Agents Phase 4,Phase 2
8 Anti-Infective Agents Phase 4,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 4,Phase 2
10 Interferon-beta Phase 4
11 Antiviral Agents Phase 4,Phase 2
12 Prednisolone acetate Phase 4
13 glucocorticoids Phase 4
14 Neuroprotective Agents Phase 4
15 Hormone Antagonists Phase 4
16 Hormones Phase 4
17 Peripheral Nervous System Agents Phase 4
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
19 Prednisolone hemisuccinate Phase 4
20 Prednisolone phosphate Phase 4
21 Fingolimod Hydrochloride Phase 4
22 Protective Agents Phase 4
23 Antiemetics Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Methylprednisolone acetate Phase 4
26 Methylprednisolone Hemisuccinate Phase 4
27 Autonomic Agents Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
30
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
31
Zidovudine Approved Phase 2 30516-87-1 35370
32
Tenofovir Approved, Investigational Phase 2 147127-20-6 464205
33
Didanosine Approved Phase 2 69655-05-6 50599
34
Enfuvirtide Approved, Investigational Phase 2 159519-65-0 16130199
35
Lenograstim Approved Phase 2 135968-09-1
36
Emtricitabine Approved, Investigational Phase 2 143491-57-0 60877
37
Zalcitabine Approved Phase 2 7481-89-2 24066
38
Vedolizumab Approved Phase 2 943609-66-3
39
Mefloquine Approved Phase 1, Phase 2 53230-10-7 4046
40 topoisomerase I inhibitors Phase 2
41 Topoisomerase Inhibitors Phase 2
42 Nucleic Acid Synthesis Inhibitors Phase 2
43 Immunoglobulins Phase 2
44 Anti-HIV Agents Phase 2
45 Antimetabolites Phase 2
46 Anti-Retroviral Agents Phase 2
47 Reverse Transcriptase Inhibitors Phase 2
48 Antimetabolites, Antineoplastic Phase 2
49 Antibodies Phase 2
50 Antibodies, Monoclonal Phase 2

Interventional clinical trials:

(show all 27)
id Name Status NCT ID Phase
1 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Recruiting NCT02769689 Phase 4
2 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4
3 Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated NCT01211665 Phase 4
4 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4
5 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3
6 Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) Completed NCT00120367 Phase 2
7 Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients Completed NCT00001048 Phase 2
8 Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) Completed NCT00002395 Phase 2
9 Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease Completed NCT00619489 Phase 2
10 Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Terminated NCT00746941 Phase 1, Phase 2
11 Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 Terminated NCT00655824 Phase 2
12 A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection Completed NCT00002270
13 A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients Completed NCT00000945
14 Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy Completed NCT02895581
15 Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome Completed NCT00342602
16 JC Virus Reactivation in Multiple Sclerosis Completed NCT02004444
17 A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine Completed NCT00002274
18 JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab Completed NCT01070836
19 Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort Completed NCT01070719
20 Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control Completed NCT01626248
21 Drug Exposure Registry for GSK2248761, an Investigational NNRTI Completed NCT01458132
22 Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) Recruiting NCT01730131
23 Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells Recruiting NCT02694783 Early Phase 1
24 Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis Recruiting NCT01981161
25 Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML) Active, not recruiting NCT01132053
26 Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant Active, not recruiting NCT01386359
27 Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy Terminated NCT01211639

Search NIH Clinical Center for Progressive Multifocal Leukoencephalopathy

Cochrane evidence based reviews: leukoencephalopathy, progressive multifocal

Genetic Tests for Progressive Multifocal Leukoencephalopathy

Anatomical Context for Progressive Multifocal Leukoencephalopathy

MalaCards organs/tissues related to Progressive Multifocal Leukoencephalopathy:

39
Brain, T Cells, Kidney, Lung, Liver, Testes, B Cells

Publications for Progressive Multifocal Leukoencephalopathy

Articles related to Progressive Multifocal Leukoencephalopathy:

(show top 50) (show all 636)
id Title Authors Year
1
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management. ( 27890176 )
2017
2
Late onset progressive multifocal leukoencephalopathy in Hodgkin lymphoma. ( 28526178 )
2017
3
Deep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy. ( 27795410 )
2017
4
Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. ( 26727910 )
2016
5
Single-molecule sequencing reveals the presence of distinct JC polyomavirus populations in patients with progressive multifocal leukoencephalopathy. ( 27571907 )
2016
6
Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review. ( 27594961 )
2016
7
Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy. ( 27965904 )
2016
8
Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. ( 27456891 )
2016
9
Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy. ( 26531763 )
2016
10
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. ( 27401179 )
2016
11
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. ( 27696299 )
2016
12
Differences in T cell cytotoxicity and cell death mechanisms between progressive multifocal leukoencephalopathy, herpes simplex virus encephalitis and cytomegalovirus encephalitis. ( 27817117 )
2016
13
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. ( 27134676 )
2016
14
Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction. ( 27056083 )
2016
15
Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. ( 26743322 )
2016
16
A case of progressive multifocal leukoencephalopathy with Takayasu arteritis and indolent adult T-cell lymphoma/leukemia. ( 26797479 )
2016
17
Extrapyramidal syndrome with generalized chorea as an atypical presentation of progressive multifocal leukoencephalopathy. ( 26968822 )
2016
18
Rehabilitation outcome of progressive multifocal leukoencephalopathy in HIV-positive patients: a report of two cases. ( 27539012 )
2016
19
Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. ( 27538654 )
2016
20
Progressive Multifocal Leukoencephalopathy in a Lung Transplant Recipient: Isolation of John Cunningham (JC) Virus from Bronchoalveolar Lavage. ( 27013844 )
2016
21
Progressive Multifocal Leukoencephalopathy in a HIV Negative, Immunocompetent Patient. ( 27529042 )
2016
22
Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod. ( 27994897 )
2016
23
A case of progressive multifocal leukoencephalopathy with chronic renal failure, whose JC virus in cerebrospinal fluid disappeared after mefloquine-mirtazapine dual therapy. ( 27645758 )
2016
24
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection. ( 27191595 )
2016
25
Cidofovir for treatment of progressive multifocal leukoencephalopathy in a newly diagnosed sarcoidosis patient - a valid therapeutic option? ( 26944175 )
2016
26
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. ( 27600113 )
2016
27
Progressive multifocal leukoencephalopathy in an immunocompetent patient. ( 27042682 )
2016
28
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. ( 27456945 )
2016
29
Possible pitfalls in the diagnostic of progressive multifocal leukoencephalopathy. ( 26754416 )
2016
30
Low-signal-intensity rim on susceptibility-weighted imaging is not a specific finding to progressive multifocal leukoencephalopathy. ( 26944139 )
2016
31
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. ( 27997580 )
2016
32
Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. ( 27401779 )
2016
33
Assessing understanding: Patients prescribed natalizumab for multiple sclerosis individual risk and symptoms of progressive multifocal leukoencephalopathy. ( 27862809 )
2016
34
Diagnostic delay in progressive multifocal leukoencephalopathy. ( 27231708 )
2016
35
Progressive multifocal leukoencephalopathy in a patient with silicosis. ( 27416854 )
2016
36
Sequential Onset of Varicella-Zoster Virus Encephalomeningitis and Progressive Multifocal Leukoencephalopathy in an Allogeneic Hematopoietic Stem Cell Transplant Recipient. ( 27938314 )
2016
37
Progressive multifocal leukoencephalopathy with bilateral middle cerebellar peduncle lesions confirmed by repeated CSF-JC virus tests and coexistence of JC virus granule cell neuronopathy. Report of a case. ( 27356732 )
2016
38
Progressive multifocal leukoencephalopathy associated with infliximab. ( 27959350 )
2016
39
Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database. ( 27736027 )
2016
40
Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. ( 27273076 )
2016
41
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. ( 27268272 )
2016
42
Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. ( 26743090 )
2016
43
Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks. ( 28039520 )
2016
44
Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. ( 26857363 )
2016
45
Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features. ( 27904430 )
2016
46
Primary cerebellar progressive multifocal leukoencephalopathy (PML) shows increased accumulation in (123)I-IMP SPECT. ( 26810523 )
2016
47
Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission. ( 26870672 )
2016
48
Progressive Multifocal Leukoencephalopathy Localized in the Cerebellum and Brainstem Associated with Idiopathic CD4(+) T Lymphocytopenia. ( 27301521 )
2016
49
Poster 346 Rehabilitation of Progressive Multifocal Leukoencephalopathy: A Case Report. ( 27673097 )
2016
50
Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8 T-Cell Infiltration and Good Response to Mefloquine Treatment. ( 27301518 )
2016

Variations for Progressive Multifocal Leukoencephalopathy

Expression for Progressive Multifocal Leukoencephalopathy

Search GEO for disease gene expression data for Progressive Multifocal Leukoencephalopathy.

Pathways for Progressive Multifocal Leukoencephalopathy

Pathways related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

(show all 31)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 BCL2 CD40LG IL2 ITGA4 STAT1 TNF
2
Show member pathways
13.14 BCL2 CD40LG IL2 RPS27A STAT1 TNF
3
Show member pathways
12.54 CD40LG IL2 ITGA4 STAT1 TNF
4
Show member pathways
12.41 BCL2 IL2 STAT1 TNF
5
Show member pathways
12.4 BCL2 IL2 STAT1 TNF
6
Show member pathways
12.19 CD40LG IL2 PDCD1 TNF
7 12.08 BCL2 STAT1 TNF
8
Show member pathways
12.06 BCL2 IL2 STAT1
9 12.05 CD40LG IL2 PDCD1 STAT1 TNF
10 12.03 HTR2A MECP2 TNF
11
Show member pathways
12 IL2 STAT1 TNF
12 11.97 CD40LG ITGA4 PDCD1
13
Show member pathways
11.93 BCL2 IL2 STAT1
14
Show member pathways
11.88 IL2 ITGA4 STAT1
15 11.85 IL2 MBP TNF
16 11.82 BCL2 STAT1 TNF
17
Show member pathways
11.76 IL2 STAT1 TNF
18 11.71 BCL2 STAT1 TNF
19 11.68 BCL2 CD40LG TNF
20 11.59 IL2 ITGA4 TNF
21
Show member pathways
11.55 CD40LG IL2 TNF
22
Show member pathways
11.5 BCL2 CD40LG TNF
23
Show member pathways
11.41 CD40LG IL2 TNF
24
Show member pathways
11.29 BCL2 CD40LG ITGA4 STAT1 TNF
25 11.25 BCL2 IL2 TNF
26 11.1 CD40LG ITGA4 PDCD1 TNF
27 11.06 BCL2 IL2
28
Show member pathways
11.03 BCL2 IL2 TNF
29 10.91 BCL2 TNF
30 10.85 BCL2 CD40LG IL2 TNF
31 10.73 BCL2 TNF

GO Terms for Progressive Multifocal Leukoencephalopathy

Cellular components related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.8 BCL2 MBP RPS27A

Biological processes related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.81 BCL2 HTR2A IL2 MECP2
2 immune response GO:0006955 9.8 CD40LG IL2 MBP TNF
3 MAPK cascade GO:0000165 9.67 IL2 MBP RPS27A TNF
4 negative regulation of apoptotic process GO:0043066 9.65 BCL2 CD40LG IL2 PDCD1 RPS27A
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.61 CD40LG RPS27A TNF
6 negative regulation of endothelial cell proliferation GO:0001937 9.52 STAT1 TNF
7 B cell differentiation GO:0030183 9.5 BCL2 CD40LG ITGA4
8 negative regulation of mitotic cell cycle GO:0045930 9.48 BCL2 TNF
9 leukocyte cell-cell adhesion GO:0007159 9.46 CD40LG ITGA4
10 leukocyte tethering or rolling GO:0050901 9.4 ITGA4 TNF
11 humoral immune response GO:0006959 9.33 BCL2 PDCD1 TNF
12 regulation of immunoglobulin secretion GO:0051023 8.96 CD40LG TNF
13 tumor necrosis factor-mediated signaling pathway GO:0033209 8.92 CD40LG RPS27A STAT1 TNF

Molecular functions related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.13 BCL2 MBP TNF
2 tumor necrosis factor receptor binding GO:0005164 8.8 CD40LG STAT1 TNF

Sources for Progressive Multifocal Leukoencephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....